Literature DB >> 12793978

In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype.

Michael Brunner1, Sodikdjon A Kodirov, Gary F Mitchell, Peter D Buckett, Katsushi Shibata, Eduardo J Folco, Linda Baker, Guy Salama, Danny P Chan, Jun Zhou, Gideon Koren.   

Abstract

Mutations in cardiac voltage-gated K+ channels cause long QT syndrome (LQTS) and sudden death. We created a transgenic mouse with a long QT phenotype (Kv1DN) by overexpression of a truncated K+ channel in the heart and investigated whether the dominant negative effect of the transgene would be overcome by the direct injection of adenoviral vectors expressing wild-type Kv1.5 (AV-Kv1.5) into the myocardium. End points at 3-10 days included electrophysiology in isolated cardiomyocytes, surface ECG, programmed stimulation of the right ventricle, and in vivo optical mapping of action potentials and repolarization gradients in Langendorff-perfused hearts. Overexpression of Kv1.5 reconstituted a 4-aminopyridine-sensitive outward K+ current, shortened the action potential duration, eliminated early afterdepolarizations, shortened the QT interval, decreased dispersion of repolarization, and increased the heart rate. Each of these changes is consistent with a physiologically significant primary effect of adenoviral expression of Kv1.5 on ventricular repolarization of Kv1DN mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12793978     DOI: 10.1152/ajpheart.00971.2002

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  16 in total

Review 1.  Regenerative therapies in electrophysiology and pacing: introducing the next steps.

Authors:  Gerard J J Boink; Michael R Rosen
Journal:  J Interv Card Electrophysiol       Date:  2010-12-16       Impact factor: 1.900

2.  Electrical hyperexcitation of lateral ventral pacemaker neurons desynchronizes downstream circadian oscillators in the fly circadian circuit and induces multiple behavioral periods.

Authors:  Michael N Nitabach; Ying Wu; Vasu Sheeba; William C Lemon; John Strumbos; Paul K Zelensky; Benjamin H White; Todd C Holmes
Journal:  J Neurosci       Date:  2006-01-11       Impact factor: 6.167

Review 3.  Gene therapy for ventricular tachyarrhythmias.

Authors:  J K Donahue
Journal:  Gene Ther       Date:  2012-04-26       Impact factor: 5.250

Review 4.  A mitochondrial redox oxygen sensor in the pulmonary vasculature and ductus arteriosus.

Authors:  Kimberly J Dunham-Snary; Zhigang G Hong; Ping Y Xiong; Joseph C Del Paggio; Julia E Herr; Amer M Johri; Stephen L Archer
Journal:  Pflugers Arch       Date:  2015-09-23       Impact factor: 3.657

Review 5.  Mouse models of long QT syndrome.

Authors:  Guy Salama; Barry London
Journal:  J Physiol       Date:  2006-10-12       Impact factor: 5.182

6.  Cortactin is required for N-cadherin regulation of Kv1.5 channel function.

Authors:  Lan Cheng; Aaron Yung; Manuel Covarrubias; Glenn L Radice
Journal:  J Biol Chem       Date:  2011-04-20       Impact factor: 5.157

Review 7.  Gene therapy to treat cardiac arrhythmias.

Authors:  Rossana Bongianino; Silvia G Priori
Journal:  Nat Rev Cardiol       Date:  2015-04-28       Impact factor: 32.419

8.  Molecular ablation of ventricular tachycardia after myocardial infarction.

Authors:  Tetsuo Sasano; Amy D McDonald; Kan Kikuchi; J Kevin Donahue
Journal:  Nat Med       Date:  2006-10-29       Impact factor: 53.440

Review 9.  Gene Therapy for Cardiac Arrhythmias.

Authors:  Tetsuo Sasano; Kentaro Takahashi; Koji Sugiyama
Journal:  Acta Cardiol Sin       Date:  2013-05       Impact factor: 2.672

10.  Increased inducibility of ventricular tachycardia and decreased heart rate variability in a mouse model for type 1 diabetes: effect of pravastatin.

Authors:  Mohammad Rajab; Hongwei Jin; Charles M Welzig; Alfred Albano; Mark Aronovitz; Yali Zhang; Ho-Jin Park; Mark S Link; Sami F Noujaim; Jonas B Galper
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-10-25       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.